All In Biotech

Drug Trial Radar · NCT06714123

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

Senicapoc in Patients With Progressive Fibrotic ILD (Interstitial Lung Disease) and IPF (Idiopathic Pulmonary Fibrosis) to Prevent Progression.

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Vejle HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Odense Patient Data Explorative Network
First posted
Dec 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease. Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if Senicapoc works to prevent lung function worsening. Participants will be asked to take 3 tablets a day for 26 weeks. Within this period, doctors will follow the participants, ask for experience of adverse events, check lung function and organ status, and participants will need to fill out quality-of-life questionnaires. A total of 5 visits are required, at initiation, after4, 13, 26 and 52 weeks. The final visit will occur 52 weeks after initiation and consist of a normal visit in the outpatient clinic where the doctor asks for relevant information regarding the period after end of administration of the study drug.

Conditions

  • Pulmonary Fibrosis, Interstitial Lung Disease
  • Idiopathic Pulmonary Fibrosis

Interventions

  • SenicapocDrug

    administering 30 mg senicapoc a day, in addition to standard of care.

  • PlaceboDrug

    Tablets similar in size and color

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of decline of forced vital capacity (FVC) in mL of predicted.Time frame: 26 weeks

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Aarhus University Hospital

    Aarhus N, Denmark · Recruiting

  • Kardiologisk Forskningsenhed 2161, Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Tartu University Hospital,

    Tartu, Estonia · Recruiting

  • Division of Respiratory Sciences, Glenfield Hospital

    Leicester, United Kingdom · Recruiting

  • University of East Anglia

    Norwich, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.